Activin A Inhibitors
1 drugsAbout Activin A
Activin A is a member of the TGF-β superfamily involved in cell growth, differentiation, apoptosis, and immune responses. Its diverse functions make it a potential therapeutic target for various conditions.
Activin A is targeted due to its involvement in key pathways related to disease progression. Currently, there is no genetic evidence available to support Activin A as a drug target.
WINREVAIR (Merck) is the only FDA-approved drug targeting Activin A, indicated for cardiovascular diseases. It is a biologic (other) modality.
Top Activin A Drugs
Merck is the only company with an approved drug targeting Activin A.
Low competition presents an opportunity for new entrants, but also indicates potential challenges.
Activin A Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Activin A, using biologic (other) modality.
Explore alternative modalities like small molecules to differentiate from existing therapies.
Activin A Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Activin A. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 2 | 1 | 0 | 67% |
| Phase 2 | 16 | 7 | 3 | 6 | 70% |
| Phase 3 | 6 | 3 | 1 | 2 | 75% |
| Phase 4 | 7 | 1 | 0 | 6 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Activin A Drug Approval Timeline (2024 - 2024)
The first and most recent drug approval for Activin A was WINREVAIR in 2024.
Recent approval suggests growing interest, but limited history indicates uncertain long-term potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 12 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Activin A. A trial counts if an approved drug acting on Activin A is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.